Dr. Robert Vescio, MD
Claim this profileCedars-Sinai Medical Center
Studies Multiple Myeloma
Studies Hematological Malignancies
5 reported clinical trials
4 drugs studied
Affiliated Hospitals
Clinical Trials Robert Vescio, MD is currently running
Cyclophosphamide After Stem Cell Transplant
for Blood Cancer
The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged \>/= 65 years with hematologic malignancies.
Recruiting1 award Phase 1
Stem Cell + CAR T-Cell Therapy
for Blood Cancers
The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease. The study will evaluate feasibility of collecting the target dose of HSCs from at least 50% of enrolled patients. The study will assess safety based on incidence and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in the first 60 days post CAR T dosing, and also through the collection of adverse events (AEs) and serious adverse events (SAEs) as well as the durability of response after treatment with HSCs with CAR T. The study follows an open-label, single-center and single non-randomized cohort design. 20 subjects with r/r hematological malignancies will be enrolled and treated to evaluate the feasibility and preliminary safety of collecting autologous HSCs and combining them with CAR T-cell therapy.
Recruiting1 award Phase 111 criteria
More about Robert Vescio, MD
Clinical Trial Related2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Robert Vescio, MD has experience with
- Penguin Cold Cap
- Omission Of The Drug Mycophenolate Mofetil
- Cyclophosphamide
- Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy
Breakdown of trials Robert Vescio, MD has run
Multiple Myeloma
Hematological Malignancies
Blood Cancers
Plasma Cell Neoplasm
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robert Vescio, MD specialize in?
Robert Vescio, MD focuses on Multiple Myeloma and Hematological Malignancies. In particular, much of their work with Multiple Myeloma has involved treating patients, or patients who are undergoing treatment.
Is Robert Vescio, MD currently recruiting for clinical trials?
Yes, Robert Vescio, MD is currently recruiting for 2 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Robert Vescio, MD has studied deeply?
Yes, Robert Vescio, MD has studied treatments such as Penguin Cold Cap, Omission of the drug mycophenolate mofetil, Cyclophosphamide.
What is the best way to schedule an appointment with Robert Vescio, MD?
Apply for one of the trials that Robert Vescio, MD is conducting.
What is the office address of Robert Vescio, MD?
The office of Robert Vescio, MD is located at: Cedars-Sinai Medical Center, Los Angeles, California 90048 United States. This is the address for their practice at the Cedars-Sinai Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.